Business Description
Nyrada Inc. is an Australian drug development company focused on creating new treatments for heart and brain conditions. Founded in 2017 and headquartered in Sydney, the company has developed Xolatryp, its primary drug candidate, which has already passed through its first round of human clinical trials targeting brain injury and stroke patients.
